Feature | June 05, 2014

ECRI Report Describes Lower-Priced Option for Treating Bone Metastases

June 5, 2014 — Magnetic resonance-guided focused ultrasound (MRgFUS) is one of the top 10 technologies to watch in 2014, according to a report released by the ECRI Institute. MRgFUS using the Exablate system by Insightec Ltd. (based in Tirat Carmel, Israel) is a relatively new noninvasive thermal ablation option, U.S. Food and Drug Administration (FDA)-approved for treating and palliating pain from bone metastases. The technology integrates high-intensity focused ultrasound and a real-time magnetic resonance imaging (MRI) system in one unit.

The therapy reportedly improves pain from bone metastases in some patients, including those who are not candidates for other treatment such as external beam radiation therapy (EBRT). Furthermore, MRgFUS is under study for treatment of other solid cancers and could potentially be positioned for use at any stage of treatment in combination with any other cancer therapy. It purportedly offers a noninvasive option with fewer side effects than surgery, chemotherapy or radiotherapy options typically used to treat cancers.

MRgFUS is well established for ablating uterine fibroids and has been approved for that use in the United States since 2004. MRgFUS was FDA-approved for palliating painful bone metastases in 2012. Bone metastases occur in more than half of patients with solid tumors, some of who have no other treatment options for palliating bone pain. For indications under study, MRgFUS is being used on patients with prostate, breast, lung, brain, liver and kidney cancers and metastatic disease.

Anticipated Utilization

Some patients with painful bone metastases are not candidates for other therapies, and thus MRgFUS may offer them a new option. Even patients who are candidates for standard EBRT might prefer MRgFUS because of its non-radioactive and targeted mechanism. Pricing is substantially lower for MRgFUS than for EBRT, although MRgFUS is not reimbursed by many U.S. third-party payers at this time, because evidence is available from only two published articles on a small number of patients. Potential for expanded use is significant, however, because several trials are under way on its use for other solid cancers.

Estimated Adoption Status

Adoption is limited at this time. According to the Focused Ultrasound Foundation, 24 centers offer MRgFUS (for uterine fibroids and/or bone metastases) in the United States as of January 2014. Of these, the company states that nine centers are offering the treatment for painful bone metastases.

Potential Health Impact

Three published articles on two studies of 160 patients (one randomized controlled trial and one small case series) reported that MRgFUS provided pain relief from bone metastases in about two-thirds of patients for up to three months after treatment (Meyer et al. 2013; Napoli et al. 2013b; Hurwitz et al. 2013). The trial (n = 142) compared MRgFUS to sham treatment. MRgFUS might have a better side-effect profile than EBRT for some patients, although risks, including necrosis and burns to skin and tissues adjacent to treatment sites, exist. MRgFUS offers a potential advantage in that it could be repeated, whereas EBRT might not be able to be repeated because of the impact of its radiation dose on a patient.

Potential Financial Impact

Initial acquisition and implementation requires major capital investment. Two options are available. A high-intensity focused ultrasound system can be fitted onto an existing MRI scanner at a cost of about $750,000 to $1.5 million, or both elements of the system can be purchased. A fully equipped MRgFUS system with a new MRI scanner costs about $2 million to $3.5 million. To accommodate larger case volumes and long treatment times, facilities might require an additional MRI scanner. The Centers for Medicare & Medicaid Services (CMS) has established a rate of about $3,300 for MRgFUS treatment, which makes reimbursement per treatment significantly lower cost than EBRT on a per patient basis.

For more information: www.ecri.org

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
Overlay Init